Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma
CONCLUSION: EA consolidation chemotherapy for transplant-ineligible, elderly patients with PCNSL improved response rates but showed a high relapse rate and short progression-free survival. The incidences of treatment-related mortality caused by hematologic toxicities and severe infections were very high, even after dose modification. Therefore, the use of EA consolidation should be reconsidered in elderly patients with PCNSL.PMID:38581718 | DOI:10.1093/oncolo/oyae059 (Source: The Oncologist)
Source: The Oncologist - April 6, 2024 Category: Cancer & Oncology Authors: Yu Ri Kim Hyunsoo Cho Soo-Jeong Kim Haerim Chung Hye Won Kook Ji Eun Jang June-Won Cheong Jin Seok Kim Source Type: research

Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma
CONCLUSION: EA consolidation chemotherapy for transplant-ineligible, elderly patients with PCNSL improved response rates but showed a high relapse rate and short progression-free survival. The incidences of treatment-related mortality caused by hematologic toxicities and severe infections were very high, even after dose modification. Therefore, the use of EA consolidation should be reconsidered in elderly patients with PCNSL.PMID:38581718 | DOI:10.1093/oncolo/oyae059 (Source: The Oncologist)
Source: The Oncologist - April 6, 2024 Category: Cancer & Oncology Authors: Yu Ri Kim Hyunsoo Cho Soo-Jeong Kim Haerim Chung Hye Won Kook Ji Eun Jang June-Won Cheong Jin Seok Kim Source Type: research

Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma
CONCLUSION: EA consolidation chemotherapy for transplant-ineligible, elderly patients with PCNSL improved response rates but showed a high relapse rate and short progression-free survival. The incidences of treatment-related mortality caused by hematologic toxicities and severe infections were very high, even after dose modification. Therefore, the use of EA consolidation should be reconsidered in elderly patients with PCNSL.PMID:38581718 | DOI:10.1093/oncolo/oyae059 (Source: The Oncologist)
Source: The Oncologist - April 6, 2024 Category: Cancer & Oncology Authors: Yu Ri Kim Hyunsoo Cho Soo-Jeong Kim Haerim Chung Hye Won Kook Ji Eun Jang June-Won Cheong Jin Seok Kim Source Type: research

Infantile osteopetrosis with delayed development, organomegaly and wandering eyes: case report
Paediatr Int Child Health. 2024 Apr 5:1-3. doi: 10.1080/20469047.2024.2335423. Online ahead of print.ABSTRACTOsteopetrosis encompasses rare inherited metabolic bone disorders with defect in the osteoclast activity. Severe forms of presentation such as malignant infantile osteopetrosis are seen in infants and milder forms in older children. The clinical presentation includes failure to thrive, severe pallor, optic atrophy and hepatosplenomegaly. The disorder is characterised by dense bone on radiography, hence the name marble bone disease. A 10-month-old boy who presented with developmental delay, failure to thrive, nystagm...
Source: Paediatrics and international child health - April 5, 2024 Category: Pediatrics Authors: Ashwini Prithvi Dhrithi Kodethoor Sushma K Sanjiv Lewin Source Type: research

Cancers, Vol. 16, Pages 1416: Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores
This study leverages the TriNetX database with more than 64,000 MF patients to assess the impact of accessible parameters on survival and complicating events, including AML transformation, cachexia, increased systemic inflammation, thrombosis and hemorrhage. Age over 65 years correlated with increased risks of death, AML transformation, thrombosis and hemorrhage. Anemia (Hb < 10 g/dL), leukocytosis (>25 × 103/µL) and thrombocytopenia (<150 × 103/µL) reduced survival and increased risks across all assessed events. Monocytosis is associa...
Source: Cancers - April 5, 2024 Category: Cancer & Oncology Authors: Max Kappenstein Nikolas von Bubnoff Tags: Article Source Type: research